Quick Answer
Beam Therapeutics Inc. reported Cash And Cash Equivalents At Carrying Value of $294.94 million for the year ending 2025.
- Beam Therapeutics Inc. showed an increase of +4.6% in Cash And Cash Equivalents At Carrying Value from 2024 to 2025.
- This data is from Beam Therapeutics Inc.'s annual report (Form 10-K), filed with the SEC on February 24, 2026.
- XBRL data for this metric is available from 2019 to 2025 (7 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q1 2019: $156.14 million | Q2 2019: $37.85 million | Q3 2019: $37.76 million | Q1 2020: $126.05 million | Q2 2020: $125.30 million | Q3 2020: $137.90 million | Q1 2021: $97.24 million | Q2 2021: $212.02 million | Q3 2021: $612.02 million | Q1 2022: $296.82 million | Q2 2022: $265.62 million | Q3 2022: $156.51 million | Q1 2023: $249.77 million | Q2 2023: $225.54 million | Q3 2023: $169.05 million | Q1 2024: $287.85 million | Q2 2024: $292.76 million | Q3 2024: $230.20 million | Q1 2025: $527.91 million | Q2 2025: $282.13 million | Q3 2025: $267.96 million.
- Over the full 7 years of available data (2019 to 2025), Beam Therapeutics Inc.'s Cash And Cash Equivalents At Carrying Value has grown by 692.4%.
- Historical annual values: Fiscal year 2025: $294.94 million | Fiscal year 2024: $281.97 million | Fiscal year 2023: $435.90 million | Fiscal year 2022: $232.77 million | Fiscal year 2021: $559.99 million | Fiscal year 2020: $162.17 million | Fiscal year 2019: $37.22 million.
- Data sourced from SEC EDGAR public filings as of August 9, 2026.
Last verified: